SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
March 12, 2003
--------------
Date of Report (Date of earliest event reported)
OSI PHARMACEUTICALS, INC.
-------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 0-15190 13-3159796
---------- ------- ----------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation) File Number) Identification No.)
58 SOUTH SERVICE ROAD
MELVILLE, NY 11747
----------------------------------------
(Address of principal executive offices)
(631) 962-2000
------------------------------
(Registrant's telephone number, including area code)
N/A
-------------------------------
(Former name or former address,
if changed since last report.)
THE CURRENT REPORT ON FORM 8-K FILED BY OSI PHARMACEUTICALS, INC. ON
MARCH 12, 2003 IS HEREBY AMENDED TO INCLUDE THE CO-PROMOTION AGREEMENT, DATED AS
OF MARCH 11, 2003, BY AND BETWEEN OSI PHARMACEUTICALS, INC. AND ARES TRADING,
S.A., AS AN EXHIBIT UNDER ITEM 7.
ITEM 7. EXHIBITS
- --------------------------------------------------------------------------------
EXHIBIT NO. DESCRIPTION
- --------------------------------------------------------------------------------
10.1* Co-Promotion Agreement, dated as of March 11, 2003, by and
between OSI Pharmaceuticals, Inc. and Ares Trading S.A.
- --------------------------------------------------------------------------------
99.1 Press release, dated March 12, 2003 (filed by the Company as an
exhibit to the Form 8-K filed on March 12, 2003 (file no.
000-05190) and incorporated herein by reference).
- --------------------------------------------------------------------------------
* Portions of this exhibit have been redacted and are the subject of a
confidential treatment request filed with the Secretary of the Securities and
Exchange Commission on March 17, 2003 pursuant to Rule 24b-2 under the
Securities Exchange Act of 1934, as amended.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: March 17, 2003 OSI PHARMACEUTICALS, INC.
By: /s/ Robert L. Van Nostrand
----------------------------------------
Robert L. Van Nostrand
Vice President and Chief Financial
Officer (Principal Financial Officer)
EXHIBIT INDEX
- --------------------------------------------------------------------------------
EXHIBIT NO. DESCRIPTION
- --------------------------------------------------------------------------------
10.1* Co-Promotion Agreement, dated as of March 11, 2003, by and
between OSI Pharmaceuticals, Inc. and Ares Trading S.A.
- --------------------------------------------------------------------------------
99.1 Press release, dated March 12, 2003 (filed by the Company as an
exhibit to the Form 8-K filed on March 12, 2003 (file no.
000-05190) and incorporated herein by reference).
- --------------------------------------------------------------------------------
* Portions of this exhibit have been redacted and are the subject of a
confidential treatment request filed with the Secretary of the Securities and
Exchange Commission on March 17, 2003 pursuant to Rule 24b-2 under the
Securities Exchange Act of 1934, as amended.